HR Execs on the Move

Esschem

www.esschem.com

 
Esschem is the worlds most respected manufacturer of specialty acrylic polymers and monomers for medical and cosmetic uses.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.esschem.com
  • 4000, Columbia Ave
    Marcus Hook, PA USA 19061
  • Phone: 800.765.9637

Executives

Name Title Contact Details
Easley Wallace
Director of Research and Development Profile

Similar Companies

F H Ayer Manufacturing Company

F H Ayer Manufacturing Company is a Chicago Heights, IL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Champions Oncology

Champions Oncology is a company that develops technology solutions and services for personalizing the development and use of oncology drugs. Their technology-enabled research platforms empower biopharma to create a comprehensive understanding of tumor ...

Hoechst AG

Hoechst AG is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BrainStorm Cell

BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn® technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. NurOwn® has been administered to over 50 patients with ALS in clinical trials conducted in Israel and the United States, and is currently being studied in a randomized, double-blind, placebo-controlled clinical trial in the United States.

Cognito Therapeutics

Cognito Therapeutics is a pioneer in non-invasive neuromodulation to treat neurodegenerative diseases and improve human cognitive performance. The company has completed multiple clinical studies demonstrating its investigational therapeutic has the potential to safely slow or stop cognitive decline and loss of brain volume in Alzheimer`s disease. Cognito has received FDA Breakthrough Device Designation for the treatment of Alzheimer`s disease and expects to start pivotal studies in 2022. The company`s technology was based on pioneering optogenetics research by scientific co-founders Professors Li-Huei Tsai and Ed Boyden at MIT.